Related Experiment Videos
[Arterial risk in type 2 diabetes: from mega-trials to prescription]
Fabrice Bonnet1, Philippe Moulin
1Fédération d'endocrinologie-diabétologie, maladies métaboliques, nutrition Hôpital Cardiovasculaire 69394 Lyon.
Abstract:
To oppose the increase in cardiovascular risk of diabetic patients several therapeutic options, validated in clinical trials, are available for the practitioner. However he is supposed to propose the most efficient combination. This strategy implies a reasonable estimation of the level of the cardiovascular absolute risk and of the risk/benefit ratio of the different options. The emerging challenge is to maintain a good observance despite the numerous and complex therapeutic associations given for life long.
Insights
Diabetic patients face high cardiovascular risk. Choosing the most effective treatment combination requires careful risk assessment and balancing benefits against potential harm for lifelong therapy.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Context:
- Diabetic patients have an elevated risk of cardiovascular disease.
- Clinical trials have established various therapeutic options for managing this risk.
- Healthcare providers must select optimal treatment strategies for individual patients.
Purpose:
- To guide practitioners in choosing the most efficient therapeutic combinations for diabetic patients.
- To emphasize the importance of accurately estimating cardiovascular absolute risk.
- To highlight the need for evaluating the risk/benefit ratio of different treatment options.
Summary:
- Effective management of cardiovascular risk in diabetes involves selecting optimal therapeutic combinations.
- Accurate assessment of absolute cardiovascular risk and the risk/benefit profile of interventions is crucial.
- Maintaining patient adherence to complex, lifelong treatment regimens presents a significant challenge.
Impact:
- Improved clinical decision-making for cardiovascular risk reduction in diabetic populations.
- Enhanced understanding of risk stratification and personalized treatment selection.
- Strategies to improve long-term patient adherence to complex diabetes and cardiovascular therapies.